SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS beat is entirely from non-recurring Takeda license revenue, not operational improvement. Monitor upcoming Phase 2 rinvatercept data in H1 2027 and any further Takeda milestones or partnership developments.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

KROS drug pipeline →

rinvatercept

● Neutral Named in this press release
Impact
Phase
Phase 2
Time to market
Unknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchWatch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.

Price Chart

Loading chart...

Executive Summary

Keros Therapeutics reported Q3 2026 net income of $14.2 million, a significant swing from a net loss of $7.3 million in Q3 2025, driven by $40 million in license revenue from Takeda. GAAP diluted EPS was $0.70, far above the consensus estimate of -$0.86, but the beat is entirely due to non-recurring license revenue. The company's cash runway extends into H2 2028, and it dosed the first patient in a Phase 2 trial of rinvatercept for DMD.

Key Financial Metrics

EPS
$0.70
est −$0.86 · +181.4%
Revenue
$40.0M
est $13.9M · +187.8% · +180.5% YoY
Rating
beat

Key Facts

  • Q3 2026 net income of $14.2 million vs net loss of $7.3 million in Q3 2025
  • GAAP diluted EPS of $0.70 vs consensus estimate of -$0.86
  • $40 million in license revenue from Takeda drove the swing to profitability
  • Research and development expenses $20.5 million, up from $19.5 million
  • General and administrative expenses $6.7 million, down from $10.1 million
  • Cash and cash equivalents $259.5 million as of September 30, 2026
  • Cash runway expected into the second half of 2028
  • First patient dosed in Phase 2 trial of rinvatercept for DMD in September 2026
  • Nominated KER-206, a nonclinical ligand trap for bone remodeling

Financial Impact

Net income of $14.2 million vs net loss of $7.3 million; GAAP diluted EPS $0.70 vs consensus -$0.86; $40M license revenue from Takeda

revenuenet incomeepscash

Risk Factors

  • EPS beat is entirely non-recurring license revenue, not sustainable
  • Company remains in net loss position on a trailing nine-month basis ($38.3M loss)
  • Clinical-stage biotech with no approved products; pipeline execution risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397005

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Viewing No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026